Krystal Cash from 2010 to 2025

KRYS Stock  USD 188.61  0.57  0.30%   
Krystal Biotech Cash yearly trend continues to be comparatively stable with very little volatility. Cash will likely drop to about 222.1 M in 2025. Cash is the total amount of money in the form of currency that Krystal Biotech has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
2016-12-31
Previous Quarter
374 M
Current Value
344.9 M
Quarterly Volatility
128.2 M
 
Covid
Check Krystal Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krystal Biotech's main balance sheet or income statement drivers, such as Net Interest Income of 31.1 M, Interest Income of 31.1 M or Depreciation And Amortization of 7 M, as well as many indicators such as Price To Sales Ratio of 14.65, Dividend Yield of 0.0 or PTB Ratio of 4.5. Krystal financial statements analysis is a perfect complement when working with Krystal Biotech Valuation or Volatility modules.
  
Check out the analysis of Krystal Biotech Correlation against competitors.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Latest Krystal Biotech's Cash Growth Pattern

Below is the plot of the Cash of Krystal Biotech over the last few years. Cash refers to the most liquid asset of Krystal Biotech, which is listed under current asset account on Krystal Biotech balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Krystal Biotech customers. The amounts must be unrestricted with restricted cash listed in a different Krystal Biotech account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Krystal Biotech's Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Krystal Biotech's overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

Krystal Cash Regression Statistics

Arithmetic Mean128,184,949
Geometric Mean25,783,009
Coefficient Of Variation109.73
Mean Deviation123,367,817
Median103,670,000
Standard Deviation140,661,935
Sample Variance19785.8T
Range356.4M
R-Value0.87
Mean Square Error5226T
R-Squared0.75
Significance0.000013
Slope25,645,911
Total Sum of Squares296786.7T

Krystal Cash History

2025222.1 M
2024344.9 M
2023358.3 M
2022161.9 M
2021341.2 M
2020268.3 M
2019187.5 M

Other Fundumenentals of Krystal Biotech

Krystal Biotech Cash component correlations

About Krystal Biotech Financial Statements

Krystal Biotech shareholders use historical fundamental indicators, such as Cash, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Krystal Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cash344.9 M222.1 M
Cash And Short Term Investments597.5 M314.7 M
Change In Cash-13.5 M-12.8 M
Free Cash Flow119.2 M125.1 M
Total Cashflows From Investing Activities-102.7 M-97.5 M
Other Cashflows From Financing Activities27 M28.4 M
Other Non Cash Items-7.1 M-7.5 M
Total Cash From Operating Activities123.4 M129.6 M
Total Cash From Financing Activities27 M25.7 M
End Period Cash Flow344.9 M222.1 M
Begin Period Cash Flow358.3 M202.5 M
Cash And Cash Equivalents Changes83.9 M78.4 M
Cash Flows Other Operating-972 K-1 M
Other Cashflows From Investing Activities115 M120.8 M
Free Cash Flow Yield 0.03  0.03 
Operating Cash Flow Per Share 4.32  4.53 
Free Cash Flow Per Share 4.17  4.38 
Cash Per Share 20.90  10.79 
Capex To Operating Cash Flow 0.03  0.04 
EV To Operating Cash Flow 33.56  35.23 
EV To Free Cash Flow 34.75  36.49 
Price To Operating Cash Flows Ratio 36.29  38.11 
Price To Free Cash Flows Ratio 37.58  39.46 
Cash Ratio 3.38  3.21 
Cash Conversion Cycle 523.20  549.36 
Operating Cash Flow Sales Ratio 0.42  0.45 
Free Cash Flow Operating Cash Flow Ratio 0.97  1.09 
Cash Flow Coverage Ratios 17.00  17.85 
Price Cash Flow Ratio 36.29  38.11 
Cash Flow To Debt Ratio 17.00  17.85 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.